Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S stock analysis
Want to see SG:T14 full AI Analyst Report?
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S (T14) Share Price & Analysis
T14 Stock Chart & Stats
- Day’s Range
- $2.50 - $2.53
- 52-Week Range
- $2.45 - $3.75
- Previous Close
- $2.53
- Volume
- N/A
- Average Volume (3M)
- 185.64K
- Market Cap
- $3.80B
- Enterprise Value
- $1.77B
- Total Cash (Recent Filing)
- $1.31B
- Total Debt (Recent Filing)
- $94.90M
- Price to Earnings (P/E)
- 33.2
- Beta
- 0.26
- Next Earnings
- Apr 01, 2027 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Jun 29, 2026
- Dividend Yield
- 13.96%
Bulls Say, Bears Say
Bulls Say
Very Low Leverage
Debt-to-equity of about 0.02 across the TTM and prior years indicates a conservative capital structure with limited solvency pressure. This gives the company flexibility to fund product development, operations, or growth initiatives without substantial balance-sheet strain.
Strong Profit Margins
High TTM gross, operating, and net margins show that the company retains meaningful economics from its pharmaceutical portfolio. This profitability provides internal funding capacity and may help absorb moderate pricing, product-mix, or revenue pressures over the next several quarters.
Positive Free Cash Flow
Positive operating and free cash flow, with free cash flow representing roughly 83% of net income, supports the quality of reported earnings. Sustained cash generation can fund investment, dividends, and working needs while reducing reliance on external financing.
Bears Say
Revenue Contraction
Persistent revenue contraction indicates weakening top-line momentum across the company’s pharmaceutical portfolio rather than a single isolated reporting-period issue. Continued declines could reduce operating leverage, limit reinvestment capacity, and make future profit growth harder to sustain.
Sharp Earnings Decline
The substantial step-down from 2025 profitability shows that earnings have normalized or come under pressure after an unusually strong period. Lower earnings power can constrain shareholder returns and reduce the company’s ability to compound investment and product-development spending.
Volatile Cash Conversion
Although cash generation remains positive, negative free-cash-flow growth and inconsistent conversion suggest that working-capital movements are affecting the timing and reliability of cash realization. This may make internally funded investment and shareholder distributions less predictable.
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S News
T14 FAQ
What was Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s price range in the past 12 months?
What is Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s market cap?
When is Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s upcoming earnings report date?
How were Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s earnings last quarter?
Is Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S overvalued?
Does Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S pay dividends?
What is Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s EPS estimate?
How many shares outstanding does Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S have?
What happened to Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S?
What is the TipRanks Smart Score and how is it calculated?
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S Stock Smart Score
Company Description
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (TPDRTG), a prominent pharmaceutical group operating with its various subsidiaries, primarily serves the People's Republic of China. Its core focus lies in the production and sale of traditional Chinese medicines, Western pharmaceuticals, and health-related products. The company's operations are distinctly divided into two key segments: Chinese Medicine and Western Medicine. Beyond manufacturing, TPDRTG is actively involved in the development and commercialization of both traditional Chinese and Western pharmaceutical and biological items. It also maintains and operates hospitals, alongside running extensive wholesale and retail networks for various medicines, biochemical products, and everyday consumer goods. Furthermore, TPDRTG extends its operations to include a suite of services such as logistics, inventory management, equipment installation, specialized medicine processing, inspection and testing, and pharmaceutical consultancy. The company's commercial strategy involves both the direct supply of its proprietary branded medicinal products to wholesalers, and acting as an intermediary to distribute third-party medicinal products to other wholesalers. Established in 1992, the company was formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited, adopting its current name in May 2022. It is headquartered in Tianjin, People's Republic of China.
- Sector
- General
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Lei Wang
- Employees
- 3,890
- Website
- www.jydrt.com.cn
- Address
- No. 17, Baidi Road, Tianjin, TI, 300193, CN
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S (T14) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 2 | 14 |
| Technical Analysis | 6 | 2 | 2 |
| Moving Averages | 0 | 0 | 12 |








